2009
DOI: 10.1007/s00277-009-0698-6
|View full text |Cite
|
Sign up to set email alerts
|

Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia

Abstract: The analysis of total plasma DNA and the monitoring of leukemic clone-specific immunoglobulin and/or T-cell receptor gene rearrangements for the evaluation of minimal residual disease (MRD) in the plasma may be useful tools for prognostic purposes or for early detection of subclinical disease recurrence in children with acute lymphoblastic leukemia (ALL). The aim of this paper is to establish reference ranges for total plasma DNA concentrations and to test the feasibility of MRD measurements employing plasma D… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

5
21
0
1

Year Published

2010
2010
2020
2020

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 33 publications
(27 citation statements)
references
References 27 publications
5
21
0
1
Order By: Relevance
“…Increased concentrations of circulating cf-DNA showed the potential power to discriminate between healthy controls and lymphoma patients. As previously reported in children with lymphoblastic leukemia, high levels of cf-DNA were detected in the plasma at diagnosis, decreased after therapy, and reached levels that were comparable to those of healthy subjects [9]. Interestingly, small increases in plasma DNA concentrations were observed during therapy in three patients who underwent complete remission, suggesting that the release of DNA into plasma may involve other unknown events.…”
Section: Discussionsupporting
confidence: 61%
See 1 more Smart Citation
“…Increased concentrations of circulating cf-DNA showed the potential power to discriminate between healthy controls and lymphoma patients. As previously reported in children with lymphoblastic leukemia, high levels of cf-DNA were detected in the plasma at diagnosis, decreased after therapy, and reached levels that were comparable to those of healthy subjects [9]. Interestingly, small increases in plasma DNA concentrations were observed during therapy in three patients who underwent complete remission, suggesting that the release of DNA into plasma may involve other unknown events.…”
Section: Discussionsupporting
confidence: 61%
“…It also has been proposed that the analysis of free plasma DNA could be a useful tool for clinical diagnostic applications as well as in the assessment of treatment efficacy [7]. Although the presence of cf-DNA has been studied in solid tumors, little information is available in hematological malig-nancies, and more specifically in non-Hodgkin lymphomas (NHLs) [8][9][10]. In a recent study, it was demonstrated that the plasma DNA level was a strong and independent prognostic biomarker in adult patients with lymphomas [10].…”
Section: Introductionmentioning
confidence: 99%
“…More accurate and sensitive quantification of malignant cell persistence post-induction can prevent undertreatment of patients with residual disease, and overtreatment of disease-free patients (31*). Studies in pediatric ALL populations demonstrate an association between adverse outcomes and persistence of MRD (3237). The role of MRD quantitation to evaluate treatment response and predict relapse is evolving in adult populations, with exploration of flow cytometry and real-time quantitative polymerase-chain-reaction techniques.…”
Section: Which Patients Should Be Transplanted?mentioning
confidence: 99%
“…Low levels of these molecules can be found even in healthy individuals; however, levels of cfDNA were found to be considerably elevated in various pathological conditions . The use of cfDNA for MRD evaluation in various hematological malignancies was described several times as having promising results . Moreover, cheap, reliable, and sensitive method of detection of these molecules and MRD in general is one of the top priorities in the field.…”
Section: Introductionmentioning
confidence: 99%